Palisade Bio (PALI) AI Stock Analysis

• Market Cap: $263.74M
• Dividend Yield: N/A
• Average Volume (3M): 4.53M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.12
• Revenue Growth: N/A
• EPS Growth: 71.95%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 149,003,200
• 10 Day Avg. Volume: 4,196,076
• 30 Day Avg. Volume: 4,525,639
• PEG Ratio: <0.01
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.19
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -258.72K
• Enterprise Value/Ebitda: -22.99
• 1Y Price Target: $11.40
• Price Target Upside: 544.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.50 ▼(-15.25% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is held down primarily by persistent losses and significant ongoing cash burn with effectively no revenue, implying continued dependence on external capital. Technical indicators also lean bearish with weak momentum and price below key short-term moving averages. Low leverage is a partial offset, but negative earnings and lack of dividend support keep the overall profile high-risk.

Positive Factors

Low leverage / balance sheet strength

Low reported debt relative to equity provides structural financial flexibility for a pre-revenue biotech. Lower interest burden reduces insolvency risk and gives management optionality to fund trials via equity or partnerships rather than costly borrowings, supporting execution through clinical milestones.

Clinical leadership added

Adding internationally recognized IBD experts strengthens the company’s clinical credibility and trial design capabilities. Durable benefits include improved investigator engagement, higher-quality endpoints and regulatory dialogue, which can de-risk development and make the program more attractive to partners and funders.

Patent coverage for lead asset

Patent protection in a major market like Japan supports a durable IP moat for the lead asset, enhancing exclusivity and licensing leverage. This structural protection can underpin future commercial negotiations, partnerships, and potential revenue capture if clinical development and approvals succeed.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow means the company is not self-funding its development. Over the medium term this creates financing risk, potential dilution, and forces management to prioritize programs or seek partnerships, which can slow development and reduce shareholder optionality.

Pre-revenue with sustained losses

Being a pre-revenue company with recurring net losses leaves the business highly dependent on clinical success to create durable value. Lack of operating revenues reduces margin visibility and increases binary risk: failure or delays in trials can materially impair prospects and the ability to attract favorable capital.

Shareholder-approved dilution capacity

Board and stockholder approval to issue additional shares and increase authorized stock signals structural reliance on equity financing. This raises the likelihood of future dilution as the company funds trials, which can weaken per-share economics and investor returns absent clear progress toward revenue or partnerships.

Palisade Bio Business Overview & Revenue Model

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

How the Company Makes Money

Palisade Bio makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its therapeutics to market, either independently or through strategic partnerships with larger pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, or milestone payments, which provide Palisade Bio with funding and shared resources. The company's revenue streams are heavily reliant on successful clinical trials, regulatory approvals, and the ability to effectively market its products to healthcare providers and patients. Additionally, Palisade Bio may secure funding through grants or investments to support its research and development efforts.

Palisade Bio Financial Statement Overview

Summary

Income statement and cash flow remain very weak for a pre-revenue biotech: revenue is effectively zero and TTM net income is about -$11.2M with TTM operating/free cash flow around -$10.1M. The balance sheet is comparatively better with low leverage (TTM debt ~$0.21M vs equity ~$3.2M), but equity has declined and ongoing losses imply continued funding risk.

Income Statement

Results reflect a pre-revenue biotech profile with persistent losses. Revenue is effectively zero in 2024 (annual) and TTM (Trailing-Twelve-Months), and profitability remains deeply negative, with TTM net income of about -$11.2M. Losses have narrowed versus 2024 (annual) (net loss about -$14.4M), but the lack of a durable revenue base and consistently negative margins keep earnings quality and visibility weak.

Balance Sheet

The balance sheet is a relative bright spot: leverage is low with TTM debt of ~$0.21M versus equity of ~$3.2M (low debt-to-equity). However, equity has fallen materially from 2022–2024 levels, and returns on equity are strongly negative in TTM (Trailing-Twelve-Months), reflecting ongoing losses and continued balance-sheet burn risk if funding conditions tighten.

Cash Flow

Cash generation remains weak, with TTM (Trailing-Twelve-Months) operating and free cash flow both around -$10.1M, indicating ongoing cash burn to fund operations. Cash burn improved versus 2024 (annual) (about -$12.2M free cash flow), but the company is still not self-funding and will likely remain dependent on external capital until revenue scales.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	250.00K	0.00	0.00	0.00
Gross Profit	-1.00K	0.00	250.00K	0.00	0.00	-146.00K
EBITDA	-11.25M	-14.42M	-12.28M	-14.24M	-24.22M	-9.94M
Net Income	-11.23M	-14.44M	-12.30M	-14.26M	-26.62M	-10.32M
Balance Sheet
Total Assets	6.97M	10.88M	14.05M	15.76M	12.51M	3.02M
Cash, Cash Equivalents and Short-Term Investments	5.23M	9.82M	12.43M	12.38M	10.49M	729.00K
Total Debt	211.00K	169.00K	369.00K	404.00K	199.00K	1.42M
Total Liabilities	3.76M	3.39M	2.74M	3.28M	5.15M	10.12M
Stockholders Equity	3.21M	7.49M	11.31M	12.48M	7.37M	-7.10M
Cash Flow
Free Cash Flow	-10.08M	-12.19M	-11.14M	-13.37M	-14.77M	-4.77M
Operating Cash Flow	-10.08M	-12.19M	-11.13M	-13.36M	-14.77M	-4.77M
Investing Cash Flow	0.00	0.00	-4.00K	-10.00K	-54.00K	-6.00K
Financing Cash Flow	7.27M	9.58M	11.19M	15.26M	24.61M	1.89M

Palisade Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.77
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 1.77 is above the 20-day moving average (MA) of 1.68, below the 50-day MA of 1.84, and above the 200-day MA of 1.32, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 84.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.

Palisade Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OBIO	52 Neutral	$247.32M	-2.41	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBP	49 Neutral	$150.43M	-1.55	-55.65%	―	―	-17.43%
PYXS	45 Neutral	$91.53M	-0.92	-87.28%	―	-82.53%	-52.00%
ELDN	44 Neutral	$196.72M	-2.18	-95.49%	―	―	72.35%
PALI	43 Neutral	$263.74M	-0.42	-228.64%	―	―	71.95%

Palisade Bio Corporate Events

Palisade Bio Approves Key Proposals at Stockholder Meeting

On December 3, 2025, Palisade Bio held a special meeting of stockholders where key proposals were approved. The stockholders approved the issuance of up to 8,637,810 shares of common stock underlying certain warrants, an amendment to increase the number of authorized shares of common stock from 280,000,000 to 300,000,000, and a proposal to adjourn the meeting if necessary to solicit additional proxies.

The most recent analyst rating on (PALI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.